Baby's hand holding its mother's finger


Latest News


Sera Prognostics Announces Early Limited Commercial Access of its PreTRM™ Test

October 19, 2015 – Sera Prognostics, Inc., today announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth.

Sera Prognostics to Present at 33rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2014 – Sera Prognostics announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the 33rd annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015.

Sera Prognostics Closes $20 Million in Series B Financing

Jan 7, 2015 – Sera Prognostics announced that it has closed $20 Million in Series B financing, led by Chione, Ltd, a European investment company, and appointed Mansoor Raza Mirza, M.D. to its Board of Directors.

Arnold L. Oronsky, Ph.D., Joins Sera’s Board of Directors

Feb 24, 2015–Sera Prognostics announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its Board of Directors. Dr. Oronsky’s addition to the Sera board occurs as the company is in the final stages of developing PreTRM™, its novel proteomic predictor for preterm birth risk, prior to its commercial launch. In addition, Douglas Fisher, M.D., joins the company’s management team as Chief Business Officer.

Bill & Melinda Gates Foundation Has Agreed to Join Series B Financing

Feb 4, 2015-Sera Prognostics announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. The additional funding will help Sera expand the reach of its proteomic technology, to develop new tests designed to predict the risk of preterm birth for women in developing countries around the world.

Stay in Touch